Authors

Latest:

Predicting Treatment Outcomes in Older Adults With AML

Measurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.

By James Barnes

Latest:

Staying Focused in Turbulent Times

When the market is volatile, people think about their financial future. With current market events as turbulent as they are, you may be concerned about their potential impact on your 401(k) account. During times like this, it is more important than ever to follow certain basic, time-tested principles of investing.

By James Radke, PhD

Latest:

The Management of Oral Mucositis in Oncology

Oral mucositis is a costly consequence of cancer therapy that can impede the efficacy of anticancer therapy. Simple preventive measures can greatly improve the patientÃ¢ï¿½ï¿½s outcome and quality of life.

By Jamie L. Studts, PhD

Latest:

Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National Model

The efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.

By Jane de Lartigue, PhD

Latest:

SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer

Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.

By Jason Broderick

Latest:

Scientists Closer to Effectively Using Cord Blood to Treat Patients with Cancer

Scientists at Fred Hutchinson Cancer Research Center in Seattle, Washington, successfully tested a mechanism that increases the number of progenitor cells extracted from a unit of human umbilical cord blood. The laboratory method potentially solves the 1- to 2-month delay in myeloid engraftment after cord blood transplantation (CBT).

By Jason M. Broderick

Latest:

Healthy Lifestyle May Reduce Likelihood of Lethal Prostate Cancer Among Those With High Genetic Risk

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

By Jeffrey J. Wargo, MD, Laurel L. Northouse, PhD, Ann M. Schafenacker, RN,and A. Mark Fendrick, MD

Latest:

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

By Jimmy Ruiz, MD

Latest:

Tissue Truly Is the Issue in Advanced Non-Small Cell Lung Cancer

The pathologic analysis of lung cancer has become increasingly complex, calling for continued attention to improving the accuracy of the assessment and reducing the amount of tissue required.

By John A. Zoidis, MD

Latest:

Pegylated Liposomal Doxorubicin (Doxil) and Drug Combinations in Multiple Myeloma

Current treatment approaches for mutiple myeloma focus on improving progression-free and overall survival. Although five-year survival rates have increased significantly over the past ten years, the prognosis of the disease is generally poor. The availability of several promising new therapies offers clinicians treatment options to further improve response rates, especially through the development of new combination regimens.

By John D. Zoidis, MD

Latest:

BIO-BUZZ: Inhibition of Angiogenesis with Bevacizumab Shows Promise in the Treatment of Recurrent or Advanced Non%u2013Small-Cell Lung Cancer

This year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.

By John D. Zoidis, MD, Prachi Patel-Predd

Latest:

News Reports: June 2007

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more

By John Zoidis, MD

Latest:

Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLL

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

By Jonathan Bertman, MD

Latest:

Influential Online Communities

As we begin 2009, I am struck by how radically different the Internet looks and acts today compared to just 10 years ago.

By Jonathan S. Batchelor

Latest:

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

By Joseph Burns

Latest:

COME HOME Program Set to Save $33.5M Over 3 Years

In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.

By Julie Beck, RN, MSN, MPH, APRN-BC

Latest:

Nurse-Driven Website Empowers Nurses to Improve Patient Care

Improving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.

By Justin Watts, MD

Latest:

Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a Decade

Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.

By Kadi-Ann Harvey-Bryan, MD

Latest:

Ablative Therapies for Small Renal Masses

A peer-reviewed summary of the ablative techniques currently available for the treatment of small renal masses.

By Keith A. Delman, MD

Latest:

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.